Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Future trends in antibiotic therapy.

S R Norrby1

  • 1Department of Infectious Diseases, University of Lund, Sweden.

Scandinavian Journal of Infectious Diseases. Supplementum
|January 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of 5-day therapy with telithromycin, a novel ketolide antibacterial, for the treatment of tonsillopharyngitis.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2004
Same author

S Ragnar Norrby--Director General of the Swedish Institute for Infectious Disease Control. Interview by Pam Das.

The Lancet. Infectious diseases·2002
Same author

Efficacy of short-course therapy with the ketolide telithromycin compared with 10 days of penicillin V for the treatment of pharyngitis/tonsillitis.

Scandinavian journal of infectious diseases·2002
Same author

Optimal treatment strategies for acute exacerbations of chronic bronchitis: high-risk patients.

Chemotherapy·2001
Same author

Levofloxacin.

Expert opinion on pharmacotherapy·2001
Same author

Urinary tract infections: disease panorama and challenges.

The Journal of infectious diseases·2001

The 1990s anticipate fewer new antibiotic registrations due to high development costs. However, advancements in fluoroquinolones, macrolides like azithromycin, and beta-lactams are expected, alongside new beta-lactamase inhibitors.

Area of Science:

  • Pharmacology
  • Microbiology
  • Infectious Diseases

Background:

  • Antibiotic development costs are rising, potentially leading to fewer new drug registrations in the 1990s compared to previous decades.
  • Increasing bacterial resistance necessitates the development of novel antimicrobial agents and strategies.

Purpose of the Study:

  • To forecast the landscape of antibiotic development and registration in the 1990s.
  • To identify emerging classes of antibiotics and resistance mechanisms.
  • To anticipate advancements in antibiotic administration and treatment.

Main Methods:

  • Review of trends in antibiotic development and registration.
  • Analysis of emerging antibiotic classes and their potential applications.
  • Projection of future challenges in antimicrobial therapy, including resistance patterns.

Related Experiment Videos

Main Results:

  • Fewer new antibiotic registrations are predicted for the 1990s due to high development costs.
  • Fluoroquinolones and macrolides (e.g., azithromycin) are expected to see significant development.
  • New beta-lactams, including carbapenems and cephalosporins, will be developed to combat resistant enterobacteria, spurring innovation in beta-lactamase inhibitors.

Conclusions:

  • The 1990s will likely witness a shift towards specialized antibiotic development, focusing on improved efficacy and resistance management.
  • While novel agents against methicillin-resistant staphylococci remain a challenge, advancements in drug delivery, such as once-daily injectables, are anticipated.